Novartis Asks 3rd Circ. To Uphold Dismissal Of Zometa Suit
Novartis urged the Third Circuit on Monday to affirm the dismissal of a suit claiming a now-deceased patient developed a serious bone disease after taking Zometa, a medication to treat high...To view the full article, register now.
Already a subscriber? Click here to view full article